During development, tissue-specific transcription factors direct differentiation decisions as undifferentiated cells adopt various fates. Uncovering how enhancers regulate the cell specificity, timing of onset, and duration of maintenance of target gene expression is thus vital for understanding normal development. We have begun to study the enhancers that control the expression of the master regulators of muscle and hypodermal specification in the C. elegans C lineage through the regulation of the terminal selector genes
elt-1 and
hlh-1.Previous work from other labs showed that PAL-1 is expressed in all C lineage cells, and induces the expression of the hypodermal regulator
elt-1 and the muscle regulator
hlh-1 as well as other targets. POP-1 inhibits the expression of
hlh-1 in the anterior C granddaughters (hypodermal progenitors), and may induce its expression in the posterior granddaughters (muscle progenitors). In contrast,
elt-1 is initially expressed in all C descendants but expression is maintained only in the anterior C granddaughters and its maintenance may be repressed by
hlh-1 in muscle progenitors. An enhancer (
enh1) of
hlh-1 has two PAL-1 binding sites but no high affinity POP-1 binding site and drives expression in embryonic blastomeres, consistent with it being responsible for
hlh-1 initiation. The cis elements controlling
elt-1 initiation in the C lineage, however, are unknown.We plan to study the role of PAL-1 and POP-1 binding sites in regulating
enh1-driven expression by incorporating
enh1 into an enhancer-reporter construct, changing the number and affinity of PAL-1 and POP-1 binding sites, and inserting modified
enh1 enhancer-reporter constructs into the genome. In parallel, we plan to identify
elt-1 enhancers bearing PAL-1 and POP-1 binding sites that drive expression in C lineage hypodermal progenitors. We will track lineal reporter expression by time-lapse confocal microscopy and automated lineage tracing. By manipulating the number, affinity and organization of binding sites in these enhancers and in synthetic enhancers, we hope to begin to understand the logic controlling embryonic gene expression.